Hybrid curcumin compounds: A new strategy for cancer treatment

Molecules

Volumn 19, Issue 12, 2014, Pages 20839-20863

  Teiten, Marie Hélène ^a   Dicato, Mario ^a   Diederich, Marc ^b  

^a LABORATOIRE DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE DU CANCER   (Luxembourg)

^b Seoul National University   (South Korea)

Author keywords

Bioavailability; Cancer; Curcumin; Hybrid molecules

Indexed keywords

ANTINEOPLASTIC AGENT; CURCUMIN;

ANALOGS AND DERIVATIVES; BIOAVAILABILITY; DRUG POTENTIATION; HUMAN; MEDICINAL CHEMISTRY; NEOPLASMS;

ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CURCUMIN; DRUG SYNERGISM; HUMANS; NEOPLASMS;

EID: 84919725343     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules191220839     Document Type: Review

References (149)

1. DeVita, V.T., Jr.; Chu, E. A history of cancer chemotherapy. Cancer Res. 2008, 68, 8643-8653.
2. Kong, D.X.; Li, X.J.; Zhang, H.Y. Where is the hope for drug discovery? Let history tell the future. Drug Discov. Today 2009, 14, 115-119.
3. Patwardhan, B.; Mashelkar, R.A. Traditional medicine-inspired approaches to drug discovery: Can ayurveda show the way forward? Drug Discov. Today 2009, 14, 804-811.
4. Rather, M.A.; Bhat, B.A.; Qurishi, M.A. Multicomponent phytotherapeutic approach gaining momentum: Is the "one drug to fit all" model breaking down? Phytomedicine 2013, 21, 1-14.
5. Mukherjee, P.K.; Wahile, A. Integrated approaches towards drug development from ayurveda and other indian system of medicines. J. Ethnopharmacol. 2006, 103, 25-35.
6. Keith, C.T.; Borisy, A.A.; Stockwell, B.R. Multicomponent therapeutics for networked systems. Nat. Rev. Drug Discov. 2005, 4, 71-78.
7. Dancey, J.E.; Chen, H.X. Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat. Rev. Drug Discov. 2006, 5, 649-659.
8. Zimmermann, G.R.; Lehar, J.; Keith, C.T. Multi-target therapeutics: When the whole is greater than the sum of the parts. Drug Discov. Today 2007, 12, 34-42.
9. Morphy, R.; Rankovic, Z. Designed multiple ligands. An emerging drug discovery paradigm. J. Med. Chem. 2005, 48, 6523-6543.
10. Medina-Franco, J.L.; Giulianotti, M.A.; Welmaker, G.S.; Houghten, R.A. Shifting from the single to the multi-target paradigm in drug discovery. Drug Discov. Today 2013, 18, 495-501.
11. Paterson, I.; Anderson, E.A. Chemistry. The renaissance of natural products as drug candidates. Science 2005, 310, 451-453.
12. Bhanot, A.; Sharma, R.; Noolvi, M.N. Natural sources as potential anti-cancer agents: A review. Int. J. Phytomed. 2011, 3, 9-26.
13. Kelkel, M.; Jacob, C.; Dicato, M.; Diederich, M. Potential of the dietary antioxidants resveratrol and curcumin in prevention and treatment of hematologic malignancies. Molecules 2010, 15, 7035-7074.
14. Orlikova, B.; Diederich, M. Power from the garden: Plant compounds as inhibitors of the hallmarks of cancer. Curr. Med. Chem. 2012, 19, 2061-2087.
15. Sawadogo, W.R.; Schumacher, M.; Teiten, M.H.; Cerella, C.; Dicato, M.; Diederich, M. A survey of marine natural compounds and their derivatives with anti-cancer activity reported in 2011. Molecules 2013, 18, 3641-3673.
16. Folmer, F.; Jaspars, M.; Dicato, M.; Diederich, M. Marine natural products as targeted modulators of the transcription factor nf-kappab. Biochem. Pharmacol. 2008, 75, 603-617.
17. Koeberle, A.; Werz, O. Multi-target approach for natural products in inflammation. Drug Discov. Today 2014, doi:10.1016/j.drudis.2014.08.006.
18. Aggarwal, B.B.; Bhatt, I.D.; Ichikawa, H.; Ahn, K.S.; Sethi, G.; Sandur, S.K.; Sundaram, C.; Seeram, N.; Shishodia, S. Curcumin: Biological and medicinal properties, In Turmeric: The Genus Curcuma; CRC Press: New york, NY, USA, 2007; Volume 45, pp. 297-368.
19. Hatcher, H.; Planalp, R.; Cho, J.; Torti, F.M.; Torti, S.V. Curcumin: From ancient medicine to current clinical trials. Cell. Mol. Life Sci. 2008, 65, 1631-1652.
20. Teiten, M.H.; Eifes, S.; Dicato, M.; Diederich, M. Curcumin-the paradigm of a multi-target natural compound with applications in cancer prevention and treatment. Toxins (Basel) 2010, 2, 128-162.
21. Teiten, M.H.; Gaigneaux, A.; Chateauvieux, S.; Billing, A.M.; Planchon, S.; Fack, F.; Renaut, J.; Mack, F.; Muller, C.P.; Dicato, M.; et al. Identification of differentially expressed proteins in curcumin-treated prostate cancer cell lines. Omics 2012, 16, 289-300.
22. Goel, A.; Kunnumakkara, A.B.; Aggarwal, B.B. Curcumin as "curecumin": From kitchen to clinic. Biochem. Pharmacol. 2008, 75, 787-809.
23. Bar-Sela, G.; Epelbaum, R.; Schaffer, M. Curcumin as an anti-cancer agent: Review of the gap between basic and clinical applications. Curr. Med. Chem. 2010, 17, 190-197.
24. Aggarwal, B.B.; Kumar, A.; Bharti, A.C. Anticancer potential of curcumin: Preclinical and clinical studies. Anticancer Res. 2003, 23, 363-398.
25. Jurenka, J.S. Anti-inflammatory properties of curcumin, a major constituent of curcuma longa: A review of preclinical and clinical research. Altern. Med. Rev. 2009, 14, 141-153.
26. Epstein, J.; Sanderson, I.R.; Macdonald, T.T. Curcumin as a therapeutic agent: The evidence from in vitro, animal and human studies. Br. J. Nutr. 2010, 103, 1545-1557.
27. Teiten, M.H.; Dicato, M.; Diederich, M. Curcumin as a regulator of epigenetic events. Mol. Nutr. Food Res. 2013, 57, 1619-1629.
28. Reuter, S.; Gupta, S.C.; Park, B.; Goel, A.; Aggarwal, B.B. Epigenetic changes induced by curcumin and other natural compounds. Genes Nutr. 2011, 6, 93-108.
29. Balogun, E.; Hoque, M.; Gong, P.; Killeen, E.; Green, C.J.; Foresti, R.; Alam, J.; Motterlini, R. Curcumin activates the haem oxygenase-1 gene via regulation of nrf2 and the antioxidant-responsive element. Biochem. J. 2003, 371, 887-895.
30. Sandur, S.K.; Pandey, M.K.; Sung, B.; Ahn, K.S.; Murakami, A.; Sethi, G.; Limtrakul, P.; Badmaev, V.; Aggarwal, B.B. Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ros-independent mechanism. Carcinogenesis 2007, 28, 1765-1773.
31. Menon, V.P.; Sudheer, A.R. Antioxidant and anti-inflammatory properties of curcumin. Adv. Exp. Med. Biol. 2007, 595, 105-125.
32. Reuter, S.; Charlet, J.; Juncker, T.; Teiten, M.H.; Dicato, M.; Diederich, M. Effect of curcumin on nuclear factor kappab signaling pathways in human chronic myelogenous k562 leukemia cells. Ann. N. Y. Acad. Sci. 2009, 1171, 436-447.
33. Teiten, M.H.; Eifes, S.; Reuter, S.; Duvoix, A.; Dicato, M.; Diederich, M. Gene expression profiling related to anti-inflammatory properties of curcumin in k562 leukemia cells. Ann. N. Y. Acad. Sci. 2009, 1171, 391-398.
34. Duvoix, A.; Blasius, R.; Delhalle, S.; Schnekenburger, M.; Morceau, F.; Henry, E.; Dicato, M.; Diederich, M. Chemopreventive and therapeutic effects of curcumin. Cancer Lett. 2005, 223, 181-190.
35. Reuter, S.; Eifes, S.; Dicato, M.; Aggarwal, B.B.; Diederich, M. Modulation of anti-apoptotic and survival pathways by curcumin as a strategy to induce apoptosis in cancer cells. Biochem. Pharmacol. 2008, 76, 1340-1351.
36. Bhandarkar, S.S.; Arbiser, J.L. Curcumin as an inhibitor of angiogenesis. Adv. Exp. Med. Biol. 2007, 595, 185-195.
37. Kunnumakkara, A.B.; Anand, P.; Aggarwal, B.B. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett. 2008, 269, 199-225.
38. Reddy, A.R.; Dinesh, P.; Prabhakar, A.S.; Umasankar, K.; Shireesha, B.; Raju, M.B. A comprehensive review on sar of curcumin. Mini Rev. Med. Chem. 2013, 13, 1769-1777.
39. Priyadarsini, K.I. Chemical and structural features influencing the biological activity of curcumin. Curr. Pharm. Des. 2013, 19, 2093-2100.
40. Jitoe-Masuda, A.; Fujimoto, A.; Masuda, T. Curcumin: From chemistry to chemistry-based functions. Curr. Pharm. Des. 2013, 19, 2084-2092.
41. Fuchs, J.R.; Pandit, B.; Bhasin, D.; Etter, J.P.; Regan, N.; Abdelhamid, D.; Li, C.; Lin, J.; Li, P.K. Structure-activity relationship studies of curcumin analogues. Bioorg. Med. Chem. Lett. 2009, 19, 2065-2069.
42. Agrawal, R.; Mishra, B.; Tyagi, E.; Nath, C.; Shukla, R. Effect of curcumin on brain insulin receptors and memory functions in stz (icv) induced dementia model of rat. Pharmacol. Res. 2010, 61, 247-252.
43. Ishida, J.; Ohtsu, H.; Tachibana, Y.; Nakanishi, Y.; Bastow, K.F.; Nagai, M.; Wang, H.K.; Itokawa, H.; Lee, K.H. Antitumor agents. Part 214: Synthesis and evaluation of curcumin analogues as cytotoxic agents. Bioorg. Med. Chem. 2002, 10, 3481-3487.
44. Sugiyama, Y.; Kawakishi, S.; Osawa, T. Involvement of the beta-diketone moiety in the antioxidative mechanism of tetrahydrocurcumin. Biochem. Pharmacol. 1996, 52, 519-525.
45. Somparn, P.; Phisalaphong, C.; Nakornchai, S.; Unchern, S.; Morales, N.P. Comparative antioxidant activities of curcumin and its demethoxy and hydrogenated derivatives. Biol. Pharm. Bull. 2007, 30, 74-78.
46. Ferrari, E.; Lazzari, S.; Marverti, G.; Pignedoli, F.; Spagnolo, F.; Saladini, M. Synthesis, cytotoxic and combined cddp activity of new stable curcumin derivatives. Bioorg. Med. Chem. 2009, 17, 3043-3052.
47. Lopez-Lazaro, M. Anticancer and carcinogenic properties of curcumin: Considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent. Mol. Nutr. Food Res. 2008, 52 (Suppl. 1), S103-S127.
48. Burgos-Moron, E.; Calderon-Montano, J.M.; Salvador, J.; Robles, A.; Lopez-Lazaro, M. The dark side of curcumin. Int. J. Cancer 2010, 126, 1771-1775.
49. Anand, P.; Kunnumakkara, A.B.; Newman, R.A.; Aggarwal, B.B. Bioavailability of curcumin: Problems and promises. Mol. Pharm. 2007, 4, 807-818.
50. st century solutions for an ancient conundrum. Curr. Drug Discov. Technol. 2009, 6, 192-199.
51. Shehzad, A.; Khan, S.; Shehzad, O.; Lee, Y.S. Curcumin therapeutic promises and bioavailability in colorectal cancer. Drugs Today (Barc.) 2010, 46, 523-532.
52. Liu, Z.; Tang, L.; Zou, P.; Zhang, Y.; Wang, Z.; Fang, Q.; Jiang, L.; Chen, G.; Xu, Z.; Zhang, H.; et al. Synthesis and biological evaluation of allylated and prenylated mono-carbonyl analogs of curcumin as anti-inflammatory agents. Eur. J. Med. Chem. 2014, 74, 671-682.
53. Tamvakopoulos, C.; Dimas, K.; Sofianos, Z.D.; Hatziantoniou, S.; Han, Z.; Liu, Z.L.; Wyche, J.H.; Pantazis, P. Metabolism and anticancer activity of the curcumin analogue, dimethoxycurcumin. Clin. Cancer Res. 2007, 13, 1269-1277.
54. Steward, W.P.; Gescher, A.J. Curcumin in cancer management: Recent results of analogue design and clinical studies and desirable future research. Mol. Nutr. Food Res. 2008, 52, 1005-1009.
55. Patwardhan, R.S.; Checker, R.; Sharma, D.; Kohli, V.; Priyadarsini, K.I.; Sandur, S.K. Dimethoxycurcumin, a metabolically stable analogue of curcumin, exhibits anti-inflammatory activities in murine and human lymphocytes. Biochem. Pharmacol. 2011, 82, 642-657.
56. Ohori, H.; Yamakoshi, H.; Tomizawa, M.; Shibuya, M.; Kakudo, Y.; Takahashi, A.; Takahashi, S.; Kato, S.; Suzuki, T.; Ishioka, C.; et al. Synthesis and biological analysis of new curcumin analogues bearing an enhanced potential for the medicinal treatment of cancer. Mol. Cancer Ther. 2006, 5, 2563-2571.
57. Yadav, B.; Taurin, S.; Rosengren, R.J.; Schumacher, M.; Diederich, M.; Somers-Edgar, T.J.; Larsen, L. Synthesis and cytotoxic potential of heterocyclic cyclohexanone analogues of curcumin. Bioorg. Med. Chem. 2010, 18, 6701-6707.
58. Kasinski, A.L.; Du, Y.; Thomas, S.L.; Zhao, J.; Sun, S.Y.; Khuri, F.R.; Wang, C.Y.; Shoji, M.; Sun, A.; Snyder, J.P.; et al. Inhibition of ikappab kinase-nuclear factor-kappab signaling pathway by 3,5-bis(2-flurobenzylidene)piperidin-4-one (ef24), a novel monoketone analog of curcumin. Mol. Pharmacol. 2008, 74, 654-661.
59. Zambre, A.P.; Kulkarni, V.M.; Padhye, S.; Sandur, S.K.; Aggarwal, B.B. Novel curcumin analogs targeting tnf-induced nf-kappab activation and proliferation in human leukemic kbm-5 cells. Bioorg. Med. Chem. 2006, 14, 7196-7204.
60. Meghwal, M.; Goswami, T.K. Piper nigrum and piperine: An update. Phytother. Res. 2013, 27, 1121-1130.
61. Srinivasan, K. Black pepper and its pungent principle-piperine: A review of diverse physiological effects. Crit Rev. Food Sci. Nutr. 2007, 47, 735-748.
62. Shoba, G.; Joy, D.; Joseph, T.; Majeed, M.; Rajendran, R.; Srinivas, P.S. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998, 64, 353-356.
63. Kondo, A.; Takeda, T.; Li, B.; Tsuiji, K.; Kitamura, M.; Wong, T.F.; Yaegashi, N. Epigallocatechin-3-gallate potentiates curcumin's ability to suppress uterine leiomyosarcoma cell growth and induce apoptosis. Int. J. Clin. Oncol. 2013, 18, 380-388.
64. Naksuriya, O.; Okonogi, S.; Schiffelers, R.M.; Hennink, W.E. Curcumin nano-formulations: A review of pharmaceutical properties and preclinical studies and clinical data related to cancer treatment. Biomaterials 2014, 35, 3365-3383.
65. Shehzad, A.; Ul-Islam, M.; Wahid, F.; Lee, Y.S. Multifunctional polymeric nanocurcumin for cancer therapy. J. Nanosci. Nanotechnol. 2014, 14, 803-814.
66. Yallapu, M.M.; Jaggi, M.; Chauhan, S.C. Curcumin nano-formulations: A future nanomedicine for cancer. Drug Discov. Today 2012, 17, 71-80.
67. Yang, R.; Zhang, S.; Kong, D.; Gao, X.; Zhao, Y.; Wang, Z. Biodegradable polymer-curcumin conjugate micelles enhance the loading and delivery of low-potency curcumin. Pharm. Res. 2012, 29, 3512-3525.
68. Mohanty, C.; Acharya, S.; Mohanty, A.K.; Dilnawaz, F.; Sahoo, S.K. Curcumin-encapsulated mepeg/pcl diblock copolymeric micelles: A novel controlled delivery vehicle for cancer therapy. Nanomedicine (Lond.) 2010, 5, 433-449.
69. Sahu, A.; Bora, U.; Kasoju, N.; Goswami, P. Synthesis of novel biodegradable and self-assembling methoxy poly(ethylene glycol)-palmitate nanocarrier for curcumin delivery to cancer cells. Acta Biomater. 2008, 4, 1752-1761.
70. Gou, M.; Men, K.; Shi, H.; Xiang, M.; Zhang, J.; Song, J.; Long, J.; Wan, Y.; Luo, F.; Zhao, X.; et al. Curcumin-loaded biodegradable polymeric micelles for colon cancer therapy in vitro and in vivo. Nanoscale 2011, 3, 1558-1567.
71. Dey, S.; Sreenivasan, K. Conjugation of curcumin onto alginate enhances aqueous solubility and stability of curcumin. Carbohydr. Polym. 2014, 99, 499-507.
72. Manju, S.; Sreenivasan, K. Conjugation of curcumin onto hyaluronic acid enhances its aqueous solubility and stability. J. Colloid Interface Sci. 2011, 359, 318-325.
73. Goyal, P.; Goyal, K.; Vijaya Kumar, S.G.; Singh, A.; Katare, O.P.; Mishra, D.N. Liposomal drug delivery systems-clinical applications. Acta Pharm. 2005, 55, 1-25.
74. Li, L.; Braiteh, F.S.; Kurzrock, R. Liposome-encapsulated curcumin: In vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 2005, 104, 1322-1331.
75. Hasan, M.; Belhaj, N.; Benachour, H.; Barberi-Heyob, M.; Kahn, C.J.; Jabbari, E.; Linder, M.; Arab-Tehrany, E. Liposome encapsulation of curcumin: Physico-chemical characterizations and effects on mcf7 cancer cell proliferation. Int. J. Pharm. 2014, 461, 519-528.
76. Saengkrit, N.; Saesoo, S.; Srinuanchai, W.; Phunpee, S.; Ruktanonchai, U.R. Influence of curcumin-loaded cationic liposome on anticancer activity for cervical cancer therapy. Colloids Surf. B Biointerfaces 2014, 114, 349-356.
77. Wang, D.; Veena, M.S.; Stevenson, K.; Tang, C.; Ho, B.; Suh, J.D.; Duarte, V.M.; Faull, K.F.; Mehta, K.; Srivatsan, E.S.; et al. Liposome-encapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor kappab by an akt-independent pathway. Clin. Cancer Res. 2008, 14, 6228-6236.
78. Li, L.; Ahmed, B.; Mehta, K.; Kurzrock, R. Liposomal curcumin with and without oxaliplatin: Effects on cell growth, apoptosis, and angiogenesis in colorectal cancer. Mol. Cancer Ther. 2007, 6, 1276-1282.
79. Narayanan, N.K.; Nargi, D.; Randolph, C.; Narayanan, B.A. Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in pten knockout mice. Int. J. Cancer 2009, 125, 1-8.
80. Singh, A.; Dilnawaz, F.; Mewar, S.; Sharma, U.; Jagannathan, N.R.; Sahoo, S.K. Composite polymeric magnetic nanoparticles for co-delivery of hydrophobic and hydrophilic anticancer drugs and mri imaging for cancer therapy. ACS Appl. Mater. Interfaces 2011, 3, 842-856.
81. Balasubramanian, S.; Girija, A.R.; Nagaoka, Y.; Iwai, S.; Suzuki, M.; Kizhikkilot, V.; Yoshida, Y.; Maekawa, T.; Nair, S.D. Curcumin and 5-fluorouracil-loaded, folate- and transferrin-decorated polymeric magnetic nano-formulation: A synergistic cancer therapeutic approach, accelerated by magnetic hyperthermia. Int. J. Nanomed. 2014, 9, 437-459.
82. Pramanik, D.; Campbell, N.R.; Das, S.; Gupta, S.; Chenna, V.; Bisht, S.; Sysa-Shah, P.; Bedja, D.; Karikari, C.; Steenbergen, C.; et al. A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy. Oncotarget 2012, 3, 640-650.
83. Misra, R.; Sahoo, S.K. Coformulation of doxorubicin and curcumin in poly(d,l-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in k562 cells. Mol. Pharm. 2011, 8, 852-866.
84. th ed.; Kufe, D.W., Weichselbaum, R.R., Bast, R.C., Jr., Gansler, T.S., Holland, J.F., Frei, E., III, Eds.; BC Decker: Hamilton, ON, USA, 2003.
85. Meunier, B. Hybrid molecules with a dual mode of action: Dream or reality? Acc. Chem. Res. 2008, 41, 69-77.
86. Chauhan, S.S.; Sharma, M.; Chauhan, P.M. Trioxaquines: Hybrid molecules for the treatment of malaria. Drug News Perspect. 2010, 23, 632-646.
87. Bajorath, J. Chemoinformatics methods for systematic comparison of molecules from natural and synthetic sources and design of hybrid libraries. J. Comput. Aided Mol. Des. 2002, 16, 431-439.
88. Jia, J.; Zhu, F.; Ma, X.; Cao, Z.; Li, Y.; Chen, Y.Z. Mechanisms of drug combinations: Interaction and network perspectives. Nat. Rev. Drug Discov. 2009, 8, 111-128.
89. Fortin, S.; Berube, G. Advances in the development of hybrid anticancer drugs. Expert Opin. Drug Discov. 2013, 8, 1029-1047.
90. Mehta, G.; Singh, V. Hybrid systems through natural product leads: An approach towards new molecular entities. Chem. Soc. Rev. 2002, 31, 324-334.
91. Nepali, K.; Sharma, S.; Kumar, D.; Budhiraja, A.; Dhar, K.L. Anticancer hybrids-A patent survey. Recent Pat. Anticancer Drug Discov. 2014, 9, 303-339.
92. Bansal, Y.; Silakari, O. Multifunctional compounds: Smart molecules for multifactorial diseases. Eur. J. Med. Chem. 2014, 76, 31-42.
93. Morphy, R.; Kay, C.; Rankovic, Z. From magic bullets to designed multiple ligands. Drug Discov. Today 2004, 9, 641-651.
94. Nepali, K.; Sharma, S.; Sharma, M.; Bedi, P.M.; Dhar, K.L. Rational approaches, design strategies, structure activity relationship and mechanistic insights for anticancer hybrids. Eur. J. Med. Chem. 2014, 77, 422-487.
95. Muregi, F.W.; Ishih, A. Next-generation antimalarial drugs: Hybrid molecules as a new strategy in drug design. Drug Dev. Res. 2010, 71, 20-32.
96. Tietze, L.F.; Bell, H.P.; Chandrasekhar, S. Natural product hybrids as new leads for drug discovery. Angew. Chem. Int. Ed. 2003, 42, 3996-4028.
97. Gademann, K. Natural produc hybrids. Chimia 2006, 60, 841-845.
98. Tsogoeva, S.B. Recent progress in the development of synthetic hybrids of natural or unnatural bioactive compounds for medicinal chemistry. Mini. Rev. Med. Chem. 2010, 10, 773-793.
99. Decker, M. Hybrid molecules incorporating natural products: Applications in cancer therapy, neurodegenerative disorders and beyond. Curr. Med. Chem. 2011, 18, 1464-1475.
100. Li, S.Y.; Wang, X.B.; Xie, S.S.; Jiang, N.; Wang, K.D.; Yao, H.Q.; Sun, H.B.; Kong, L.Y. Multifunctional tacrine-flavonoid hybrids with cholinergic, beta-amyloid-reducing, and metal chelating properties for the treatment of alzheimer's disease. Eur. J. Med. Chem. 2013, 69, 632-646.
101. Mizuno, C.S.; Paul, S.; Suh, N.; Rimando, A.M. Synthesis and biological evaluation of retinoid-chalcones as inhibitors of colon cancer cell growth. Bioorg. Med. Chem. Lett. 2010, 20, 7385-7387.
102. Mao, F.; Yan, J.; Li, J.; Jia, X.; Miao, H.; Sun, Y.; Huang, L.; Li, X. New multi-target-directed small molecules against alzheimer's disease: A combination of resveratrol and clioquinol. Org. Biomol. Chem. 2014, 12, 5936-5944.
103. Belluti, F.; Fontana, G.; dal Bo, L.; Carenini, N.; Giommarelli, C.; Zunino, F. Design, synthesis and anticancer activities of stilbene-coumarin hybrid compounds: Identification of novel proapoptotic agents. Bioorg. Med. Chem. 2010, 18, 3543-3550.
104. Singh, N.; Sarkar, J.; Sashidhara, K.V.; Ali, S.; Sinha, S. Anti-tumour activity of a novel coumarin-chalcone hybrid is mediated through intrinsic apoptotic pathway by inducing puma and altering bax/bcl-2 ratio. Apoptosis 2014, 19, 1017-1028.
105. Abdel-Aziz, M.; Park, S.E.; Abuo-Rahma Gel, D.; Sayed, M.A.; Kwon, Y. Novel n-4-piperazinyl-ciprofloxacin-chalcone hybrids: Synthesis, physicochemical properties, anticancer and topoisomerase i and ii inhibitory activity. Eur. J. Med. Chem. 2013, 69, 427-438.
106. Wu, J.H.; Batist, G.; Zhou, J.; Geng, G.; Lin, R.; Li, Y. Hybrid-Ionone and Curcumin Molecules as Anticancer Agents. U.S. Patent 8470889 B2, 25 June 2013.
107. Dimauro, T.M. Methylated Curcumin-Resveratrol Hybrid Molecules for Treating Cancer. U.S. Patent 8350093 B2, 8 January 2013.
108. Dimauro, T.M. Curcumin-Resveratrol Hybrids. European Patent 2749552 A1, 2 July 2014.
109. Mishra, S.; Kapoor, N.; Mubarak Ali, A.; Pardhasaradhi, B.V.; Kumari, A.L.; Khar, A.; Misra, K. Differential apoptotic and redox regulatory activities of curcumin and its derivatives. Free Radic. Biol. Med. 2005, 38, 1353-1360.
110. Mantovani, F.; Banks, L. The human papillomavirus e6 protein and its contribution to malignant progression. Oncogene 2001, 20, 7874-7887.
111. Singh, A.K.; Misra, K. Human papilloma virus 16 e6 protein as a target for curcuminoids, curcumin conjugates and congeners for chemoprevention of oral and cervical cancers. Interdiscip. Sci. 2013, 5, 112-118.
112. Dubey, S.K.; Sharma, A.K.; Narain, U.; Misra, K.; Pati, U. Design, synthesis and characterization of some bioactive conjugates of curcumin with glycine, glutamic acid, valine and demethylenated piperic acid and study of their antimicrobial and antiproliferative properties. Eur. J. Med. Chem. 2008, 43, 1837-1846.
113. Singh, D.V.; Agarwal, S.; Singh, P.; Godbole, M.M.; Misra, K. Curcumin conjugates induce apoptosis via a mitochondrion dependent pathway in mcf-7 and mda-mb-231 cell lines. Asian Pac. J. Cancer Prev. 2013, 14, 5797-5804.
114. Trecul, A.; Morceau, F.; Dicato, M.; Diederich, M. Dietary compounds as potent inhibitors of the signal transducers and activators of transcription (stat) 3 regulatory network. Genes Nutr. 2012, 7, 111-125.
115. Kumar, A.; Bora, U. Molecular docking studies on inhibition of stat3 dimerization by curcumin natural derivatives and its conjugates with amino acids. Bioinformation 2012, 8, 988-993.
116. Aguilar-Rojas, A.; Huerta-Reyes, M. Human gonadotropin-releasing hormone receptor-activated cellular functions and signaling pathways in extra-pituitary tissues and cancer cells (review). Oncol. Rep. 2009, 22, 981-990.
117. Limonta, P.; Montagnani Marelli, M.; Mai, S.; Motta, M.; Martini, L.; Moretti, R.M. Gnrh receptors in cancer: From cell biology to novel targeted therapeutic strategies. Endocr. Rev. 2012, 33, 784-811.
118. Montagnani Marelli, M.; Moretti, R.M.; Januszkiewicz-Caulier, J.; Motta, M.; Limonta, P. Gonadotropin-releasing hormone (gnrh) receptors in tumors: A new rationale for the therapeutical application of gnrh analogs in cancer patients? Curr. Cancer Drug Targets 2006, 6, 257-269.
119. Grundker, C.; Gunthert, A.R.; Westphalen, S.; Emons, G. Biology of the gonadotropin-releasing hormone system in gynecological cancers. Eur. J. Endocrinol. 2002, 146, 1-14.
120. Aggarwal, S.; Ndinguri, M.W.; Solipuram, R.; Wakamatsu, N.; Hammer, R.P.; Ingram, D.; Hansel, W. [dlys(6)]-luteinizing hormone releasing hormone-curcumin conjugate inhibits pancreatic cancer cell growth in vitro and in vivo. Int. J. Cancer 2011, 129, 1611-1623.
121. Shi, Q.; Wada, K.; Ohkoshi, E.; Lin, L.; Huang, R.; Morris-Natschke, S.L.; Goto, M.; Lee, K.H. Antitumor agents 290. Design, synthesis, and biological evaluation of new lncap and pc-3 cytotoxic curcumin analogs conjugated with anti-androgens. Bioorg. Med. Chem. 2012, 20, 4020-4031.
122. Souriau, C.; Hudson, P.J. Recombinant antibodies for cancer diagnosis and therapy. Expert Opin. Biol. Ther. 2003, 3, 305-318.
123. List, T.; Neri, D. Immunocytokines: A review of molecules in clinical development for cancer therapy. Clin. Pharmacol. 2013, 5, 29-45.
124. Xin, L.; Cao, J.; Cheng, H.; Zeng, F.; Hu, X.; Shao, J. Human monoclonal antibodies in cancer therapy: A review of recent developments. Front Biosci. (Landmark Ed.) 2013, 18, 765-772.
125. Cole, L.A. Hcg variants, the growth factors which drive human malignancies. Am. J. Cancer Res. 2012, 2, 22-35.
126. Vyas, H.K.; Pal, R.; Vishwakarma, R.; Lohiya, N.K.; Talwar, G.P. Selective killing of leukemia and lymphoma cells ectopically expressing hcgbeta by a conjugate of curcumin with an antibody against hcgbeta subunit. Oncology 2009, 76, 101-111.
127. Sung, B.; Kunnumakkara, A.B.; Sethi, G.; Anand, P.; Guha, S.; Aggarwal, B.B. Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model. Mol. Cancer Ther. 2009, 8, 959-970.
128. Liu, K.; Zhang, D.; Chojnacki, J.; Du, Y.; Fu, H.; Grant, S.; Zhang, S. Design and biological characterization of hybrid compounds of curcumin and thalidomide for multiple myeloma. Org. Biomol. Chem. 2013, 11, 4757-4763.
129. Juneja, M.; Vanam, U.; Paranthaman, S.; Bharathan, A.; Keerthi, V.S.; Reena, J.K.; Rajaram, R.; Rajasekharan, K.N.; Karunagaran, D. 4-amino-2-arylamino-5-indoloyl/cinnamoythiazoles, analogs of topsentin-class of marine alkaloids, induce apoptosis in hela cells. Eur. J. Med. Chem. 2013, 63, 474-483.
130. Koon, H.; Leung, A.W.; Yue, K.K.; Mak, N.K. Photodynamic effect of curcumin on npc/cne2 cells. J. Environ. Pathol. Toxicol. Oncol. 2006, 25, 205-215.
131. Banerjee, S.; Prasad, P.; Hussain, A.; Khan, I.; Kondaiah, P.; Chakravarty, A.R. Remarkable photocytotoxicity of curcumin in hela cells in visible light and arresting its degradation on oxovanadium(iv) complex formation. Chem. Commun. 2012, 48, 7702-7704.
132. Prasad, P.; Khan, I.; Kondaiah, P.; Chakravarty, A.R. Mitochondria-targeting oxidovanadium(iv) complex as a near-ir light photocytotoxic agent. Chemistry 2013, 19, 17445-17455.
133. Banik, B.; Somyajit, K.; Nagaraju, G.; Chakravarty, A.R. Oxovanadium(iv) complexes of curcumin for cellular imaging and mitochondria targeted photocytotoxicity. Dalton Trans. 2014, 43, 13358-13369.
134. Balaji, B.; Somyajit, K.; Banik, B.; Nagaraju, G.; Chakravarty, A.R. Photoactivated DNA cleavage and anticancer activity of oxovanadium(iv) complexes of curcumin. Inorg. Chim. Acta 2013, 400, 142-150.
135. Kanakis, C.D.; Tarantilis, P.A.; Polissiou, M.G.; Tajmir-Riahi, H.A. Probing the binding sites of resveratrol, genistein, and curcumin with milk beta-lactoglobulin. J. Biomol. Struct. Dyn. 2013, 31, 1455-1466.
136. Li, M.; Ma, Y.; Ngadi, M.O. Binding of curcumin to beta-lactoglobulin and its effect on antioxidant characteristics of curcumin. Food Chem. 2013, 141, 1504-1511.
137. Tsujii, H.; Yamada, T.; Kajimoto, T.; Tanaka, R.; Tokuda, H.; Hasegawa, J.; Hamashima, Y.; Node, M. Hybrids of 3alpha-methoxyserrat-14-en-21beta-ol (pj-1) and 3beta-methoxyserrat-14-en-21beta-ol (pj-2) and various anti-oxidants as cancer chemopreventive agents. Eur. J. Med. Chem. 2010, 45, 2191-2197.
138. Nakagawa-Goto, K.; Yamada, K.; Nakamura, S.; Chen, T.H.; Chiang, P.C.; Bastow, K.F.; Wang, S.C.; Spohn, B.; Hung, M.C.; Lee, F.Y.; et al. Antitumor agents. 258. Syntheses and evaluation of dietary antioxidant-Taxoid conjugates as novel cytotoxic agents. Bioorg. Med. Chem. Lett. 2007, 17, 5204-5209.
139. Nakagawa-Goto, K.; Nakamura, S.; Bastow, K.F.; Nyarko, A.; Peng, C.Y.; Lee, F.Y.; Lee, F.C.; Lee, K.H. Antitumor agents. 256. Conjugation of paclitaxel with other antitumor agents: Evaluation of novel conjugates as cytotoxic agents. Bioorg. Med. Chem. Lett. 2007, 17, 2894-2898.
140. Tanaka, R.; Tsujii, H.; Yamada, T.; Kajimoto, T.; Amano, F.; Hasegawa, J.; Hamashima, Y.; Node, M.; Katoh, K.; Takebe, Y. Novel 3alpha-methoxyserrat-14-en-21beta-ol (pj-1) and 3beta-methoxyserrat-14-en-21beta-ol (pj-2)-curcumin, kojic acid, quercetin, and baicalein conjugates as hiv agents. Bioorg. Med. Chem. 2009, 17, 5238-5246.
141. st century. Curr. Neuropharmacol. 2013, 11, 338-378.
142. Chin, D.; Huebbe, P.; Pallauf, K.; Rimbach, G. Neuroprotective properties of curcumin in Alzheimer's disease-merits and limitations. Curr. Med. Chem. 2013, 20, 3955-3985.
143. Reinke, A.A.; Gestwicki, J.E. Structure-activity relationships of amyloid beta-aggregation inhibitors based on curcumin: Influence of linker length and flexibility. Chem. Biol. Drug Des. 2007, 70, 206-215.
144. Li, Y.; Peng, P.; Tang, L.; Hu, Y.; Sheng, R. Design, synthesis and evaluation of rivastigmine and curcumin hybrids as site-activated multi-target-directed ligands for Alzheimer's disease therapy. Bioorg. Med. Chem. 2014, 22, 4717-4725.
145. Lenhart, J.A.; Ling, X.; Gandhi, R.; Guo, T.L.; Gerk, P.M.; Brunzell, D.H.; Zhang, S. "Clicked" bivalent ligands containing curcumin and cholesterol as multifunctional abeta oligomerization inhibitors: Design, synthesis, and biological characterization. J. Med. Chem. 2010, 53, 6198-6209.
146. Chojnacki, J.E.; Liu, K.; Yan, X.; Toldo, S.; Selden, T.; Estrada, M.; Rodriguez-Franco, M.I.; Halquist, M.S.; Ye, D.; Zhang, S. Discovery of 5-(4-hydroxyphenyl)-3-oxo-pentanoic acid [2-(5-methoxy-1h-indol-3-yl)-ethyl]-amide as a neuroprotectant for alzheimer's disease by hybridization of curcumin and melatonin. ACS Chem. Neurosci. 2014, 5, 690-699.
147. Lapchak, P.A.; McKim, J.M., Jr. Ceetox analysis of cnb-001 a novel curcumin-based neurotrophic/neuroprotective lead compound to treat stroke: Comparison with nxy-059 and radicut. Transl. Stroke Res. 2011, 2, 51-59.
148. Abdel Aziz, M.T.; Motawi, T.; Rezq, A.; Mostafa, T.; Fouad, H.H.; Ahmed, H.H.; Rashed, L.; Sabry, D.; Senbel, A.; Al-Malki, A.; et al. Effects of a water-soluble curcumin protein conjugate vs. Pure curcumin in a diabetic model of erectile dysfunction. J. Sex. Med. 2012, 9, 1815-1833.
149. Zaahkouk, A.M.; Abdel Aziz, M.T.; Rezq, A.M.; Atta, H.M.; Fouad, H.H.; Ahmed, H.H.; Sabry, D.; Yehia, M.H. Efficacy of a novel water-soluble curcumin derivative versus sildenafil citrate in mediating erectile function. Int. J. Impot. Res. 2014, doi:10.1038/ijir.2014.24.